Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?

References

• Enzinger FM. Epitheloid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer. 1970 Nov;26(5):1029–1041. doi: 10.1002/1097-0142(197011)26:5<1029:AID-CNCR2820260510>3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Ziegler A, Vens M. Generalized estimating equations. notes on the choice of the working correlation matrix. Methods Inf Med. 2010;49(5):421–425. discussion 426-32. doi: 10.3414/ME10-01-0026
   PubMedGoogle Scholar
• Rakheja D, Wilson KS, Meehan J, et al. “Proximal-type” and classic epithelioid sarcomas represent a clinicopathologic continuum: case report. Pediatr Dev Pathol. 2005 Jan;8(1):105–114.
   PubMed Web of Science ®Google Scholar
• Alves A, Constantinidou A, Thway K, et al. The evolving management of epithelioid sarcoma. Eur J Cancer Care (Engl). 2021 Nov;30(6):e13489.
   PubMed Web of Science ®Google Scholar
• Jawad MU, Extein J, Min ES, et al. Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res. 2009 Nov;467(11):2939–2948.
   PubMed Web of Science ®Google Scholar
• Ross HM, Lewis JJ, Woodruff JM, et al. Epithelioid sarcoma: clinical behavior and prognostic factors of survival. Ann Surg Oncol. 1997 Sep;4(6):491–495.
   PubMed Web of Science ®Google Scholar
• Baratti D, Pennacchioli E, Casali PG, et al. Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2007 Dec;14(12):3542–3551.
   PubMed Web of Science ®Google Scholar
• Livi L, Shah N, Paiar F, et al. Treatment of epithelioid sarcoma at the royal marsden hospital. Sarcoma. 2003;7(3–4):149–152. doi: 10.1080/13577140310001644760
   PubMedGoogle Scholar
• Chase DR, Enzinger FM. Epithelioid sarcoma. diagnosis, prognostic indicators, and treatment. Am J Surg Pathol. 1985 Apr;9(4):241–263. doi: 10.1097/00000478-198504000-00001
   PubMed Web of Science ®Google Scholar
• Spillane AJ, Thomas JM, Fisher C. Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol. 2000 Apr;7(3):218–225. doi: 10.1007/BF02523657
   PubMed Web of Science ®Google Scholar
• Biegel JA, Zhou JY, Rorke LB, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999 Jan 1;59(1):74–79.
   PubMed Web of Science ®Google Scholar
• Brenca M, Rossi S, Lorenzetto E, et al. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ. Mol Cancer Ther. 2013 Jun;12(6):1060–1072.
   PubMed Web of Science ®Google Scholar
• Hornick JL, Dal Cin P, Fletcher CD. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol. 2009 Apr;33(4):542–550. doi: 10.1097/PAS.0b013e3181882c54
   PubMed Web of Science ®Google Scholar
• Modena P, Lualdi E, Facchinetti F, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res. 2005 May 15;65(10):4012–4019. doi: 10.1158/0008-5472.CAN-04-3050
   PubMed Web of Science ®Google Scholar
• Wang X, Haswell JR, Roberts CW. Molecular pathways: sWI/SNF (BAF) complexes are frequently mutated in cancer–mechanisms and potential therapeutic insights. Clin Cancer Res. 2014 Jan 1;20(1):21–27. doi: 10.1158/1078-0432.CCR-13-0280
   PubMed Web of Science ®Google Scholar
• Jagani Z, Mora-Blanco EL, Sansam CG, et al. Loss of the tumor suppressor snf5 leads to aberrant activation of the hedgehog-gli pathway. Nat Med. 2010 Dec;16(12):1429–1433.
   PubMed Web of Science ®Google Scholar
• Mora-Blanco EL, Mishina Y, Tillman EJ, et al. Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene. 2014 Feb 13;33(7):933–938. doi: 10.1038/onc.2013.37
   PubMed Web of Science ®Google Scholar
• Phelan ML, Sif S, Narlikar GJ, et al. Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits. Mol Cell. 1999 Feb;3(2):247–253.
   PubMed Web of Science ®Google Scholar
• Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010 Oct 19;18(4):316–328. doi: 10.1016/j.ccr.2010.09.006
   PubMed Web of Science ®Google Scholar
• Rasmussen SV, Jin JX, Bickford LR, et al. Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. Clin Transl Med. 2022 Jul;12(7):e961.
   PubMed Web of Science ®Google Scholar
• Frezza AM, Sigalotti L, Savio ED, et al. Epitheliod sarcoma: molecular insights into proximal versus classic variant. J Clin Oncol. 2020;38(15_suppl):e23552–e23552. doi: 10.1200/JCO.2020.38.15_suppl.e23552
   Web of Science ®Google Scholar
• Kato H, Hatori M, Kokubun S, et al. CA125 expression in epithelioid sarcoma. Jpn J Clin Oncol. 2004 Mar;34(3):149–154.
   PubMed Web of Science ®Google Scholar
• Kawashima H, Hoshino M, Ogose A, et al. CA125 expression in epithelioid sarcoma: production and secretion by epithelioid sarcoma cells in vitro and clinical feature. Cancer Res. 2008;68(9_Supplement):2191–2191.
   Google Scholar
• Haas RL, Delaney TF, O’Sullivan B, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):572–580. doi: 10.1016/j.ijrobp.2012.01.062
   PubMed Web of Science ®Google Scholar
• Davis AM, O’Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005 Apr;75(1):48–53.
   PubMed Web of Science ®Google Scholar
• O’Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002 Jun 29;359(9325):2235–2241. doi: 10.1016/S0140-6736(02)09292-9
   PubMed Web of Science ®Google Scholar
• Bogani G, Fucà G, Maltese G, et al. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol. 2016 Nov;143(2):443–447.
   PubMed Web of Science ®Google Scholar
• Frezza AM, Jones RL, Lo Vullo S, et al. Anthracycline, gemcitabine, and pazopanib in epithelioid sarcoma: a multi-institutional case series. JAMA Oncol. 2018 Sep 1;4(9):e180219. doi: 10.1001/jamaoncol.2018.0219
   PubMed Web of Science ®Google Scholar
• Jones RL, Constantinidou A, Olmos D, et al. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug;35(4):351–357.
   PubMed Web of Science ®Google Scholar
• Touati N, Schöffski P, Litière S, et al. European organisation for research and treatment of cancer soft tissue and bone sarcoma group experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy. Clin Oncol. 2018 Jul;30(7):448–454. R Coll Radiol. doi: 10.1016/j.clon.2018.02.065
   PubMed Web of Science ®Google Scholar
• Pink D, Richter S, Gerdes S, et al. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis. Oncology. 2014;87(2):95–103. doi: 10.1159/000362602
   PubMed Web of Science ®Google Scholar
• Gounder MM, Merriam P, Ratan R, et al. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer. 2021 Apr 15;127(8):1311–1317. doi: 10.1002/cncr.33365
   PubMed Web of Science ®Google Scholar
• Anderson SE, Keohan ML, D’Adamo DR, et al. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma. 2006;2006:15947. doi: 10.1155/SRCM/2006/15947
   PubMedGoogle Scholar
• Tariq Z, Ghose A, Bawany MZ, et al. A case report of complete remission of pulmonary metastases from epithelioid sarcoma to navelbine chemotherapy. Am J Ther. 2012 Mar;19(2):e95–7.
   PubMed Web of Science ®Google Scholar
• Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423–1432.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Schoffski P, Jones R, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). J Clin Oncol. 2019;37(15_suppl):11003–11003. doi: 10.1200/JCO.2019.37.15_suppl.11003
   Web of Science ®Google Scholar
• Nakamura T, Matsumine A, Kawai A, et al. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese musculoskeletal oncology group (JMOG) study. Cancer. 2016 May 1;122(9):1408–1416. doi: 10.1002/cncr.29961
   PubMed Web of Science ®Google Scholar
• Irimura S, Nishimoto K, Kikuta K, et al. Successful treatment with pazopanib for multiple lung metastases of inguinal epithelioid sarcoma: a case report. Case Rep Oncol. 2015 Sep;8(3):378–384.
   PubMedGoogle Scholar
• Schuetze SM, Bolejack V, Choy E, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017 Jan 1;123(1):90–97. doi: 10.1002/cncr.30379
   PubMed Web of Science ®Google Scholar
• Penot P, Bouaziz JD, Battistella M, et al. Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate. Br J Dermatol. 2013 Apr;168(4):871–873.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 Jan;21(1):121–133.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6(1):24. doi: 10.1186/s13569-016-0064-0
   PubMedGoogle Scholar
• D’Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018 Mar;19(3):416–426.
   PubMed Web of Science ®Google Scholar
• Pecora A, Halpern S, Weber M, et al. Rapid and complete response to combination anti-ctla-4 and anti-pd-1 checkpoint inhibitor therapy in a patient with stage iv refractory end-stage epithelioid sarcoma: a case report. J Immunother. 2020 Nov;43(9):286–290.
   PubMed Web of Science ®Google Scholar
• Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019 Jun;20(6):837–848.
   PubMed Web of Science ®Google Scholar
• Martin-Broto J, Hindi N, Grignani G, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial. J Immunother Cancer. 2020 Nov;8(2):e001561.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Shoushtari AN, Keohan ML, et al. Combined KIT and CTLA-4 blockade in patients with refractory gist and other advanced sarcomas: a phase ib study of dasatinib plus ipilimumab. Clin Cancer Res. 2017 Jun 15;23(12):2972–2980. doi: 10.1158/1078-0432.CCR-16-2349
   PubMed Web of Science ®Google Scholar
• Imura Y, Yasui H, Outani H, et al. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer. 2014 Aug 7;13(1):185. doi: 10.1186/1476-4598-13-185
   PubMedGoogle Scholar
• Xie X, Ghadimi MP, Young ED, et al. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011 Sep 15;17(18):5901–5912. doi: 10.1158/1078-0432.CCR-11-0660
   PubMed Web of Science ®Google Scholar
• Cascio MJ, O’Donnell RJ, Horvai AE. Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare. Mod Pathol. 2010 Apr;23(4):574–580. doi: 10.1038/modpathol.2010.2
   PubMed Web of Science ®Google Scholar
• Sakharpe A, Lahat G, Gulamhusein T, et al. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. Oncology. 2011;16(4):512–522. doi: 10.1634/theoncologist.2010-0174
   Google Scholar
• Ino Y, Gotoh M, Sakamoto M, et al. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):365–370. doi: 10.1073/pnas.012425299
   PubMed Web of Science ®Google Scholar
• Izumi T, Oda Y, Hasegawa T, et al. Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor. Mod Pathol. 2006 Jun;19(6):820–831.
   PubMed Web of Science ®Google Scholar
• Bum-Erdene K, Yeh IJ, Gonzalez-Gutierrez G, et al. Small-molecule cyanamide pan-tead·yap1 covalent antagonists. J Med Chem. 2023 Jan 12;66(1):266–284. doi: 10.1021/acs.jmedchem.2c01189
   PubMed Web of Science ®Google Scholar
• Forrest SJ, Al-Ibraheemi A, Doan D, et al. Genomic and immunologic characterization of ini1-deficient pediatric cancers. Clin Cancer Res. 2020 Jun 15;26(12):2882–2890. doi: 10.1158/1078-0432.CCR-19-3089
   PubMed Web of Science ®Google Scholar
• Boxberg M, Steiger K, Lenze U, et al. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy. Oncoimmunology. 2018;7(3):e1389366. doi: 10.1080/2162402X.2017.1389366
   PubMed Web of Science ®Google Scholar
• Kim C, Kim EK, Jung H, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016 Jul 8;16(1):434. doi: 10.1186/s12885-016-2451-6
   PubMedGoogle Scholar
• Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003 Jun 15;101(12):4878–4886. doi: 10.1182/blood-2002-07-1956
   PubMed Web of Science ®Google Scholar
• Aspeslagh S, Morel D, Soria JC, et al. Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Ann Oncol. 2018 Apr 1;29(4):812–824. doi: 10.1093/annonc/mdy050
   PubMed Web of Science ®Google Scholar
• Qiu J, Sharma S, Rollins RA, et al. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020 Aug;12(15):1415–1430.
   PubMed Web of Science ®Google Scholar
• Zingg D, Arenas-Ramirez N, Sahin D, et al. The histone methyltransferase ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 2017 Jul 25;20(4):854–867. doi: 10.1016/j.celrep.2017.07.007
   PubMed Web of Science ®Google Scholar
• Zhou L, Mudianto T, Ma X, et al. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-pd-1 resistance in head and neck cancer. Clin Cancer Res. 2020 Jan 1;26(1):290–300. doi: 10.1158/1078-0432.CCR-19-1351
   PubMed Web of Science ®Google Scholar
• Morel KL, Sheahan AV, Burkhart DL, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 Apr;2(4):444–456.
   PubMedGoogle Scholar